Amarin Corp Plc (AMRN)

[ziploc_1]

No gV has been approved for reducing CVD....Amarin needs to get this information out to Docs.

One way to do this is to have an independent group run a randomized study of a group new patients, just starting Vascepa, and comparing that group to a group of patients just starting gV...to determine which group has more fish burping...When Vascepa proves to be superior in this study, Amarin can discuss the patented gelatin capsule as a reason for the decreased fish burping, presenting this information to Docs and reminding them that ONLY Vascepa has been approved by the FDA for reducing CVD...and that gV is NOT THE SAME as Vascepa.